Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Ganglioneuroblastoma
100%
Pediatrics
69%
Tumor
36%
Neoplasm
33%
Pediatric Cancer
31%
Organoid
30%
Childhood Cancer
26%
Malignant Neoplasm
24%
Cancer
21%
Diseases
21%
Precision Oncology
20%
Solid Malignant Neoplasm
18%
Therapeutic Target
18%
Personalized Medicine
17%
Targeted Therapy
15%
Genetics
15%
Adolescence
14%
Neuroblastoma Cell
13%
Overall Survival
11%
Immunotherapy
11%
RNA Sequence
10%
T Cell
9%
Experimental Therapy
9%
Clinical Trial
9%
Rhabdoid Tumor
8%
DNA Repair
8%
Drug Sensitivity
8%
Biological Marker
8%
Carcinogenesis
8%
Rhabdomyosarcoma
8%
Molecular Profiling
7%
Disease Predisposition
7%
Messenger RNA
7%
Cancer Epidemiology
7%
Neuroblastoma Cell Line
7%
Drug Screening
7%
High Throughput Screening
7%
Cas9
7%
Clustered Regularly Interspaced Short Palindromic Repeat
7%
Ganglioglioma
6%
Cancer Susceptibility
6%
Tumor Regression
6%
Whole Genome Sequencing
6%
Chemotherapy
6%
Disease Course
6%
Intracranial Tumor
6%
Progression Free Survival
6%
Cell Therapy
6%
Mitogen-Activated Protein Kinase
6%
Liquid Biopsy
5%
DNA Damage Response
5%
Catecholamine
5%
Medulloblastoma
5%
Anaplastic Lymphoma Kinase
5%
Poly ADP Ribose Polymerase
5%
Urinary System
5%
ALK Inhibitor
5%
Chromosome Aberration
5%
Event Free Survival
5%
Keyphrases
Neuroblastoma
95%
Pediatric
26%
Tumor
22%
High-risk Neuroblastoma
19%
Pediatric Tumors
17%
Therapeutic Target
15%
Neuroblastoma Cells
12%
Precision Oncology
11%
Childhood Cancer
10%
MYCN Amplification
10%
Tumor Subtype
9%
Single-cell RNA Sequencing (scRNA-seq)
9%
High Risk
9%
Extracranial Solid Tumor
9%
Drug Development
9%
Cyclin-dependent Kinase 4 (CDK4)
9%
High-throughput Screening
9%
Pediatric Brain Tumor
8%
Pediatric Malignancy
8%
Pediatric Cancer
8%
Organoids
8%
Cancer Research
8%
Murine Double Minute 2 (MDM2)
8%
Anti-GD2 Antibody
8%
Targeted Treatment
7%
Targeted Drugs
7%
Neutrophils
7%
Fluorescence-guided Surgery
7%
Drug Development Strategy
7%
Risk Factors
7%
T Cells
7%
Pediatric Oncology
7%
Transcriptome
7%
Aberrations
7%
Catecholamines
6%
Clinical Course
6%
Tumor Organoids
6%
Clinical Data
6%
Enhancer of Zeste Homolog 2 (EZH2)
6%
Neuroblastoma Cell Line
6%
Dinutuximab
6%
RAS-MAPK Pathway
6%
Children with Cancer
6%
Complete Remission
6%
Vulnerability
6%
Malignancy
6%
Overall Survival
6%
High-throughput
5%
Targeted Probe
5%
Genetic Modification
5%
Patient-derived Organoids
5%
Exon Deletion
5%
Therapeutic Approaches
5%
Therapeutic Vulnerability
5%
Combination Strategy
5%
Drug Sensitivity
5%
Clinical Features
5%
Patient Tumor
5%
Biochemistry, Genetics and Molecular Biology
Pediatrics
41%
RNA Sequence
19%
Targeted Therapy
14%
Genomics
14%
Transcription Factors
13%
Tumor Progression
13%
Drug Sensitivity
11%
P53
9%
Gene Expression
9%
Mitogen-Activated Protein Kinase
9%
Aurora A Kinase
7%
Alpha Thalassemia/Mental Retardation X-Linked
7%
Whole Genome Sequencing
7%
CRISPR/Cas9
7%
Gene Mutation
7%
Drug Screening
6%
Germline
6%
Germ Cell
6%
Enhancer Region
6%
Transcriptome
5%
DNA Methylation
5%
High Throughput Screening
5%
RNA Sequencing
5%
Genetics
5%